Drug seen effective in personality disorder

Drug seen effective in personality disorder Friday, May 26, 2006
NEW YORK (Reuters Health) – The anti-psychotic drug Abilify (aripiprazole) appears to be a safe and effective treatment for patients with borderline personality disorder, often leading to improvements in health-related quality of life and interpersonal problems, a study suggests.

Personality disorder is a type of mental illness in which people have trouble functioning with others. It can be associated with depression and psychopathological symptoms. A few neuroleptic agents have been used in therapy for patients with borderline personality disorder.

In their study, Dr. Marius K. Nickel, of University Clinic, Regensburg, Germany, and colleagues randomly assigned 52 adults diagnosed with borderline personality disorder to 15 mg/day Abilify or placebo for 8 weeks. The findings are published in the American Journal of Psychiatry this month.

Compared with the placebo group, the Abilify group had significantly greater improvements in several symptoms including depression, anxiety and anger, Nickel and colleagues report.

Self-injury, another characteristic symptom, occurred in both groups over the course of treatment, but only two episodes occurred in the Abilify group compared with seven in the placebo group.

The most common side effects reported with Abilify were headache, insomnia, nausea, numbness, constipation and anxiety. No serious side effects or suicide attempts were observed, and none of the patients had significant changes in weight.

The researchers recommend that larger studies be conducted to see if this findings can be replicated and to establish how long the effects of drug treatment last.

SOURCE: American Journal of Psychiatry, May 2006.

Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Related MedlinePlus Pages:

* Medicines –
* Personality Disorders –

Date last updated: 30 May 2006

Leave a Reply